April 12th 2024
Data showed that 87.8% of treated patients and 96.1% of patients who completed the study achieved normal 24-hour mean plasma testosterone values (222 to 800 ng/dL) at 90-day follow-up.
September 28th 2023
Medical Crossfire®: Expert Exchanges to Maximize Clinical Outcomes for Patients with CRPC Through Evidence-Based Personalized Therapy
View More
How the Experts Treat NMIBC During a BCG Shortage—Integrating Recent Approvals and Investigational Therapies
View More
Staying Abreast of the Prostate Cancer Treatment Paradigm From Risk Stratification to Adaptive Sequencing Strategies
View More
Everything You Need to Know About PARP Inhibitor Combinations in Prostate Cancer Care: Why? For Whom? And When?
View More
Clinical Case Vignette Series: Integrating Recent Data into Practice to Improve Outcomes in Advanced Prostate Cancer
View More
Medical Crossfire®: How Will Emerging Data Inform Treatment Planning for Patients With Prostate Cancer in the Community?
View More
Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?
View More
New consensus: PSA cuts PCa deaths in men 50-69
September 3rd 2013For men aged 50–69 years, PSA testing reduces prostate cancer-specific mortality and the incidence of metastatic disease, according to a new multinational consensus statement on early detection of prostate cancer, which also calls for prostate cancer diagnosis to be unlinked from treatment for the disease.
Advances in TURP: Focus on the science
September 1st 2013Most urologists agree that surgical removal of the enlarged portion of the prostate is the most effective and durable way to manage lower urinary tract symptoms in men secondary to BPH. Where it gets interesting is deriving urologic consensus on the best way to achieve that goal.
Genetic variants linked to lower urinary tract symptoms in African-Americans
September 1st 2013In a study of African-American men, researchers say they’ve linked two genetic variants to severity of lower urinary tract symptoms related to BPH, giving scientists insight into the higher risk facing African-Americans.
Testosterone doesn’t worsen lower urinary tract symptoms in men with BPH
September 1st 2013A new study has found that testosterone replacement doesn’t worsen lower urinary tract symptoms related to an enlarged prostate. In fact, many men saw their symptoms improve, apparently with little effect on their prostate gland.
Plasma vaporization found superior to TURis, TURP for BPH
August 9th 2013As follow-up lengthens in a prospective, randomized, controlled trial, men who underwent bipolar plasma vaporization of the prostate for BPH using the “button” vapo-resection electrode continue to demonstrate significantly better symptom scores and voiding characteristics compared to their counterparts treated by bipolar transurethral resection in saline or monopolar transurethral resection of the prostate.
Frozen sperm from azoospermic men as viable as fresh
August 9th 2013Testicular sperm extraction of frozen sperm taken by biopsy in azoospermic men is as effective as fresh sperm taken by biopsy in helping couples conceive through in vitro fertilization (IVF), according to a study from Washington University School of Medicine in St. Louis.
For BPH, bipolar, monopolar transurethral resection of the prostate show similar clinical efficacy
August 9th 2013In the treatment of BPH, while both bipolar-transurethral resection of the prostate (B-TURP) and monopolar-TURP (M-TURP) have similar clinical efficacy, B-TURP is associated with fewer adverse events, according to a recent systematic review of the two modalities.
AUA, allies critical of GAO self-referral report
August 7th 2013Major organizations representing urology are livid at the conclusions of a new report by the U.S. Government Accountability Office, which basically accuses urology practices with in-office intensity-modulated radiation therapy facilities of ripping off Medicare.
GAO takes aim at urologist self-referral-again
August 5th 2013Provision of intensity-modulated radiation therapy services performed by self-referring groups “increased rapidly” between 2006 and 2010 while the rate declined for non-self-referring groups, according to a report from the Government Accountability Office.
Prostate cancer screening decision aids don’t change men’s minds
August 5th 2013Men who receive decision aids about prostate cancer screening appear to have significantly increased knowledge about screening and less conflict about what to do, but the decision aids show little impact on their decision whether or not to be screened.
Technology doesn’t raise overall PCa therapy rate
July 24th 2013The rate of therapy for localized prostate cancer does not rise in markets with higher penetration of robotic surgical technology and intensity-modulated radiation therapy, according to a study presented at the American Society of Clinical Oncology annual meeting in Chicago.
Agent shows benefit in PDE-5 incomplete responders
July 23rd 2013A greater percentage of men who had an incomplete response to as-needed phosphodiesterase type-5 inhibitor treatment returned to normal erectile function when given tadalafil (Cialis) once daily, compared to placebo, researchers reported.